Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream

Francesca I. Ezughah, Andrew G. Affleck, Alan Evans, Sally H. Ibbotson, Colin J. Fleming

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    Background: Although the effectiveness of daily dosing regimens of 5% imiquimod cream for the treatment of superficial basal cell carcinomas (sBCC) has been documented by recent studies, concerns about long-term outcome remain. The majority of efficacy data is based on clinical clearance and limited histological examination which may not identify tumour presence at the periphery. Objective: To assess the efficacy of 5% imiquimod cream for sBCC using detailed histological assessment 1 year after completion of treatment. Methods: Nine individuals with biopsy-proven sBCC treated with 5% imiquimod cream 1 year previously and who remained clinically clear were recruited. Paraffin-embedded excision specimens from the original tumour site were extensively examined by a dermatopathologist. Examination and analysis of frozen sections of the original tumour perimeter using Mohs' micrographic surgery (MMS) were then performed. Results: Eight of nine individuals, 89% (95% CI 56% to 97%) were histologically clear of sBCC at 52 weeks. One individual had a single focus of sBCC at one lateral margin. Conclusion: The results show agreement between the clinical and histological assessment of tumour clearance. However, the persistence of disease in one patient, although limited, indicates the need for cautious long-term follow-up studies on the use of 5% imiquimod cream for sBCC.

    Original languageEnglish
    Pages (from-to)156-158
    Number of pages3
    JournalJournal of Dermatological Treatment
    Volume19
    Issue number3
    DOIs
    Publication statusPublished - 2008

    Keywords

    • basal cell carcinoma
    • histological clearance
    • imiquimod

    Cite this

    @article{a58fe14b078047edbc207067b071cf84,
    title = "Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5{\%} cream",
    abstract = "Background: Although the effectiveness of daily dosing regimens of 5{\%} imiquimod cream for the treatment of superficial basal cell carcinomas (sBCC) has been documented by recent studies, concerns about long-term outcome remain. The majority of efficacy data is based on clinical clearance and limited histological examination which may not identify tumour presence at the periphery. Objective: To assess the efficacy of 5{\%} imiquimod cream for sBCC using detailed histological assessment 1 year after completion of treatment. Methods: Nine individuals with biopsy-proven sBCC treated with 5{\%} imiquimod cream 1 year previously and who remained clinically clear were recruited. Paraffin-embedded excision specimens from the original tumour site were extensively examined by a dermatopathologist. Examination and analysis of frozen sections of the original tumour perimeter using Mohs' micrographic surgery (MMS) were then performed. Results: Eight of nine individuals, 89{\%} (95{\%} CI 56{\%} to 97{\%}) were histologically clear of sBCC at 52 weeks. One individual had a single focus of sBCC at one lateral margin. Conclusion: The results show agreement between the clinical and histological assessment of tumour clearance. However, the persistence of disease in one patient, although limited, indicates the need for cautious long-term follow-up studies on the use of 5{\%} imiquimod cream for sBCC.",
    keywords = "basal cell carcinoma, histological clearance, imiquimod",
    author = "Ezughah, {Francesca I.} and Affleck, {Andrew G.} and Alan Evans and Ibbotson, {Sally H.} and Fleming, {Colin J.}",
    year = "2008",
    doi = "10.1080/09546630701759603",
    language = "English",
    volume = "19",
    pages = "156--158",
    journal = "Journal of Dermatological Treatment",
    issn = "0954-6634",
    publisher = "Informa Healthcare",
    number = "3",

    }

    Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. / Ezughah, Francesca I.; Affleck, Andrew G.; Evans, Alan; Ibbotson, Sally H.; Fleming, Colin J.

    In: Journal of Dermatological Treatment, Vol. 19, No. 3, 2008, p. 156-158.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream

    AU - Ezughah, Francesca I.

    AU - Affleck, Andrew G.

    AU - Evans, Alan

    AU - Ibbotson, Sally H.

    AU - Fleming, Colin J.

    PY - 2008

    Y1 - 2008

    N2 - Background: Although the effectiveness of daily dosing regimens of 5% imiquimod cream for the treatment of superficial basal cell carcinomas (sBCC) has been documented by recent studies, concerns about long-term outcome remain. The majority of efficacy data is based on clinical clearance and limited histological examination which may not identify tumour presence at the periphery. Objective: To assess the efficacy of 5% imiquimod cream for sBCC using detailed histological assessment 1 year after completion of treatment. Methods: Nine individuals with biopsy-proven sBCC treated with 5% imiquimod cream 1 year previously and who remained clinically clear were recruited. Paraffin-embedded excision specimens from the original tumour site were extensively examined by a dermatopathologist. Examination and analysis of frozen sections of the original tumour perimeter using Mohs' micrographic surgery (MMS) were then performed. Results: Eight of nine individuals, 89% (95% CI 56% to 97%) were histologically clear of sBCC at 52 weeks. One individual had a single focus of sBCC at one lateral margin. Conclusion: The results show agreement between the clinical and histological assessment of tumour clearance. However, the persistence of disease in one patient, although limited, indicates the need for cautious long-term follow-up studies on the use of 5% imiquimod cream for sBCC.

    AB - Background: Although the effectiveness of daily dosing regimens of 5% imiquimod cream for the treatment of superficial basal cell carcinomas (sBCC) has been documented by recent studies, concerns about long-term outcome remain. The majority of efficacy data is based on clinical clearance and limited histological examination which may not identify tumour presence at the periphery. Objective: To assess the efficacy of 5% imiquimod cream for sBCC using detailed histological assessment 1 year after completion of treatment. Methods: Nine individuals with biopsy-proven sBCC treated with 5% imiquimod cream 1 year previously and who remained clinically clear were recruited. Paraffin-embedded excision specimens from the original tumour site were extensively examined by a dermatopathologist. Examination and analysis of frozen sections of the original tumour perimeter using Mohs' micrographic surgery (MMS) were then performed. Results: Eight of nine individuals, 89% (95% CI 56% to 97%) were histologically clear of sBCC at 52 weeks. One individual had a single focus of sBCC at one lateral margin. Conclusion: The results show agreement between the clinical and histological assessment of tumour clearance. However, the persistence of disease in one patient, although limited, indicates the need for cautious long-term follow-up studies on the use of 5% imiquimod cream for sBCC.

    KW - basal cell carcinoma

    KW - histological clearance

    KW - imiquimod

    U2 - 10.1080/09546630701759603

    DO - 10.1080/09546630701759603

    M3 - Article

    C2 - 18569271

    VL - 19

    SP - 156

    EP - 158

    JO - Journal of Dermatological Treatment

    JF - Journal of Dermatological Treatment

    SN - 0954-6634

    IS - 3

    ER -